Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

INTRODUCTION: Epigenetic modifications play an important role in progression and development of resistance in (V600E)BRAF positive metastatic melanoma. Therefore, we hypothesized that the action of vemurafenib (BRAF inhibitor) can be made more effective by combining with low dose decitabine (a DNA m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Zakharia, Yousef, Monga, Varun, Swami, Umang, Bossler, Aaron D., Freesmeier, Michele, Frees, Melanie, Khan, Mirza, Frydenlund, Noah, Srikantha, Rithu, Vanneste, Marion, Henry, Michael, Milhem, Mohammed
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5687680/
https://ncbi.nlm.nih.gov/pubmed/29179510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21269
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars